Global Public Health
As the world’s largest, most diversified healthcare products company, we are driven to foster better health for more people in more places around the world.
While the world has made significant progress in providing improved healthcare, major gaps remain. Exacerbated by the COVID-19 pandemic, bolder, smarter approaches are needed to overcome the drastic inequity in access to care—now more than ever.
Through a dedicated Global Public Health (GPH) organization that combines world-class research and development, global strategy and external affairs capabilities, and local implementation and impact teams, we put the world’s most underserved at the heart of everything we do—measuring our success in lives improved.
Expand
Collapse
While the world has made significant progress in providing improved healthcare, major gaps remain. Exacerbated by the COVID-19 pandemic, bolder, smarter approaches are needed to overcome the drastic inequity in access to care—now more than ever.
Through a dedicated Global Public Health (GPH) organization that combines world-class research and development, global strategy and external affairs capabilities, and local implementation and impact teams, we put the world’s most underserved at the heart of everything we do—measuring our success in lives improved.
Featured efforts that advance equitable access to care
Latest news
Latest news
Johnson & Johnson joins other companies in signing a landmark communiqué on expanded global access for COVID-19
In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.
Latest news
Latest news
4 ways Johnson & Johnson has worked to make access to medicines around the world more equitable
The Access to Medicine Index, a ranking of pharmaceutical companies’ work to distribute medications to low- and middle-income countries, just named Johnson & Johnson #3 on its biennial list, underscoring the company’s deep history of ensuring people in underserved communities receive the treatments they need.
How we deliver equitable access to care
01
Develop Holistic and Impactful Solutions to Ensure Our Transformational Innovations Are Available, Affordable and Accessible
02
Enable, Advance and Unlock Breakthrough Science for Global Health Challenges
03
Focus, Convene and Advocate to Move the World’s Health Forward, Faster
Johnson & Johnson has a long history of developing innovative medicines and technologies, and we continue to strengthen our R&D pipeline to turn science into solutions for the world’s most vulnerable communities.
Ruxandra Draghia-Akli, M.D., Ph.D.
Global Head, Global Public Health Research & Development,
Johnson & Johnson
Johnson & Johnson
ESG Strategy
Our commitment to advancing global health equity is a core priority embedded in our environmental, social and governance (ESG) strategy to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.
News & press releases
Janssen announces promising antiviral activity against dengue in a phase 2a human challenge model
Early-stage research suggests potential to prevent and treat all dengue serotypes With no treatments available, dengue infects up to 400 million people each year and the pace of outbreaks is increasing.[1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
The new Satellite Center will work to accelerate discovery research against flaviviruses, including dengue, which impacts 400 million people each year This effort will build on Johnson & Johnson’s decade-long legacy and ongoing collaboration with Duke-NUS in early-stage dengue research The Satellite Center is the first Asia Pacific site in Johnson & Johnson’s network of research collaborations aimed at addressing entrenched and emerging pandemic threats
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
At 16-months median follow-up, CARVYKTI® significantly improved progression-free survival compared to two standard treatmentsi Data presented at the 2023 ASCO and EHA Annual Meetings and published in The New England Journal of Medicine
Johnson & Johnson Marks More Than 2 Billion Doses of Medicine Donated to Date to Help Combat Intestinal Worms
Millions of children in more than 50 countries have received deworming medication since the donation program began in 2006, enabling them to grow and thrive The Company continues to build upon its longstanding commitment to address neglected tropical diseases through R&D efforts targeting dengue and leprosy